Marico Ltd: Intrinsic Value & Share Price Analysis

Share Price and Basic Stock Data

Last Updated: November 6, 2025, 9:33 pm

Competitors of Marico Ltd

All Competitor Stocks of Marico Ltd

Quarterly Result

Last Updated: August 20, 2025, 7:10 am

Below is a detailed analysis of the quarterly data for Marico Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:

• For Sales, as of Jun 2025, the value is 3,259.00 Cr.. The value appears strong and on an upward trend. It has increased from 2,730.00 Cr. (Mar 2025) to 3,259.00 Cr., marking an increase of 529.00 Cr..
• For Expenses, as of Jun 2025, the value is 2,604.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 2,272.00 Cr. (Mar 2025) to 2,604.00 Cr., marking an increase of 332.00 Cr..
• For Operating Profit, as of Jun 2025, the value is 655.00 Cr.. The value appears strong and on an upward trend. It has increased from 458.00 Cr. (Mar 2025) to 655.00 Cr., marking an increase of 197.00 Cr..
• For OPM %, as of Jun 2025, the value is 20.00%. The value appears strong and on an upward trend. It has increased from 17.00% (Mar 2025) to 20.00%, marking an increase of 3.00%.
• For Other Income, as of Jun 2025, the value is 56.00 Cr.. The value appears strong and on an upward trend. It has increased from 47.00 Cr. (Mar 2025) to 56.00 Cr., marking an increase of 9.00 Cr..
• For Interest, as of Jun 2025, the value is 10.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 12.00 Cr. (Mar 2025) to 10.00 Cr., marking a decrease of 2.00 Cr..
• For Depreciation, as of Jun 2025, the value is 45.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 52.00 Cr. (Mar 2025) to 45.00 Cr., marking a decrease of 7.00 Cr..
• For Profit before tax, as of Jun 2025, the value is 656.00 Cr.. The value appears strong and on an upward trend. It has increased from 441.00 Cr. (Mar 2025) to 656.00 Cr., marking an increase of 215.00 Cr..
• For Tax %, as of Jun 2025, the value is 22.00%. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 22.00%.
• For Net Profit, as of Jun 2025, the value is 513.00 Cr.. The value appears strong and on an upward trend. It has increased from 345.00 Cr. (Mar 2025) to 513.00 Cr., marking an increase of 168.00 Cr..
• For EPS in Rs, as of Jun 2025, the value is 3.89. The value appears strong and on an upward trend. It has increased from 2.65 (Mar 2025) to 3.89, marking an increase of 1.24.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Profit & Loss - Annual Report

Last Updated: October 15, 2025, 4:52 am

Balance Sheet

Last Updated: July 25, 2025, 2:47 pm

Below is a detailed analysis of the balance sheet data for Marico Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:

• For Equity Capital, as of Mar 2025, the value is 129.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 129.00 Cr..
• For Reserves, as of Mar 2025, the value is 3,846.00 Cr.. The value appears strong and on an upward trend. It has increased from 3,703.00 Cr. (Mar 2024) to 3,846.00 Cr., marking an increase of 143.00 Cr..
• For Borrowings, as of Mar 2025, the value is 554.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 528.00 Cr. (Mar 2024) to 554.00 Cr., marking an increase of 26.00 Cr..
• For Other Liabilities, as of Mar 2025, the value is 3,752.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 2,993.00 Cr. (Mar 2024) to 3,752.00 Cr., marking an increase of 759.00 Cr..
• For Total Liabilities, as of Mar 2025, the value is 8,281.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 7,353.00 Cr. (Mar 2024) to 8,281.00 Cr., marking an increase of 928.00 Cr..
• For Fixed Assets, as of Mar 2025, the value is 2,758.00 Cr.. The value appears strong and on an upward trend. It has increased from 2,724.00 Cr. (Mar 2024) to 2,758.00 Cr., marking an increase of 34.00 Cr..
• For CWIP, as of Mar 2025, the value is 40.00 Cr.. The value appears to be declining and may need further review. It has decreased from 44.00 Cr. (Mar 2024) to 40.00 Cr., marking a decrease of 4.00 Cr..
• For Investments, as of Mar 2025, the value is 1,590.00 Cr.. The value appears strong and on an upward trend. It has increased from 602.00 Cr. (Mar 2024) to 1,590.00 Cr., marking an increase of 988.00 Cr..
• For Other Assets, as of Mar 2025, the value is 3,893.00 Cr.. The value appears to be declining and may need further review. It has decreased from 3,983.00 Cr. (Mar 2024) to 3,893.00 Cr., marking a decrease of 90.00 Cr..
• For Total Assets, as of Mar 2025, the value is 8,281.00 Cr.. The value appears strong and on an upward trend. It has increased from 7,353.00 Cr. (Mar 2024) to 8,281.00 Cr., marking an increase of 928.00 Cr..

Notably, the Reserves (3,846.00 Cr.) exceed the Borrowings (554.00 Cr.), indicating a solid financial buffer.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Free Cash Flow

Financial Efficiency Indicators

Share Holding Pattern

Mutual Fund Holdings

Key Financial Ratios

After reviewing the key financial ratios for Marico Ltd, here is a detailed analysis based on the latest available data and recent trends:

• For FaceValue, as of Mar 25, the value is 1.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 1.00.
• For Basic EPS (Rs.), as of Mar 25, the value is 12.59. This value is within the healthy range. It has increased from 11.46 (Mar 24) to 12.59, marking an increase of 1.13.
• For Diluted EPS (Rs.), as of Mar 25, the value is 12.56. This value is within the healthy range. It has increased from 11.43 (Mar 24) to 12.56, marking an increase of 1.13.
• For Cash EPS (Rs.), as of Mar 25, the value is 14.23. This value is within the healthy range. It has increased from 12.87 (Mar 24) to 14.23, marking an increase of 1.36.
• For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 30.81. It has decreased from 32.32 (Mar 24) to 30.81, marking a decrease of 1.51.
• For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 30.81. It has decreased from 32.32 (Mar 24) to 30.81, marking a decrease of 1.51.
• For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 83.96. It has increased from 74.83 (Mar 24) to 83.96, marking an increase of 9.13.
• For PBDIT / Share (Rs.), as of Mar 25, the value is 18.19. This value is within the healthy range. It has increased from 16.81 (Mar 24) to 18.19, marking an increase of 1.38.
• For PBIT / Share (Rs.), as of Mar 25, the value is 16.81. This value is within the healthy range. It has increased from 15.58 (Mar 24) to 16.81, marking an increase of 1.23.
• For PBT / Share (Rs.), as of Mar 25, the value is 16.40. This value is within the healthy range. It has increased from 15.02 (Mar 24) to 16.40, marking an increase of 1.38.
• For Net Profit / Share (Rs.), as of Mar 25, the value is 12.85. This value is within the healthy range. It has increased from 11.64 (Mar 24) to 12.85, marking an increase of 1.21.
• For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 12.63. This value is within the healthy range. It has increased from 11.48 (Mar 24) to 12.63, marking an increase of 1.15.
• For PBDIT Margin (%), as of Mar 25, the value is 21.66. This value is within the healthy range. It has decreased from 22.45 (Mar 24) to 21.66, marking a decrease of 0.79.
• For PBIT Margin (%), as of Mar 25, the value is 20.02. This value exceeds the healthy maximum of 20. It has decreased from 20.82 (Mar 24) to 20.02, marking a decrease of 0.80.
• For PBT Margin (%), as of Mar 25, the value is 19.53. This value is within the healthy range. It has decreased from 20.06 (Mar 24) to 19.53, marking a decrease of 0.53.
• For Net Profit Margin (%), as of Mar 25, the value is 15.30. This value exceeds the healthy maximum of 10. It has decreased from 15.55 (Mar 24) to 15.30, marking a decrease of 0.25.
• For NP After MI And SOA Margin (%), as of Mar 25, the value is 15.04. This value is within the healthy range. It has decreased from 15.34 (Mar 24) to 15.04, marking a decrease of 0.30.
• For Return on Networth / Equity (%), as of Mar 25, the value is 40.99. This value is within the healthy range. It has increased from 38.64 (Mar 24) to 40.99, marking an increase of 2.35.
• For Return on Capital Employeed (%), as of Mar 25, the value is 36.90. This value is within the healthy range. It has decreased from 40.38 (Mar 24) to 36.90, marking a decrease of 3.48.
• For Return On Assets (%), as of Mar 25, the value is 19.53. This value is within the healthy range. It has decreased from 19.95 (Mar 24) to 19.53, marking a decrease of 0.42.
• For Total Debt / Equity (X), as of Mar 25, the value is 0.09. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 0.09.
• For Asset Turnover Ratio (%), as of Mar 25, the value is 1.37. It has increased from 1.34 (Mar 24) to 1.37, marking an increase of 0.03.
• For Current Ratio (X), as of Mar 25, the value is 2.07. This value is within the healthy range. It has increased from 1.64 (Mar 24) to 2.07, marking an increase of 0.43.
• For Quick Ratio (X), as of Mar 25, the value is 1.56. This value is within the healthy range. It has increased from 1.09 (Mar 24) to 1.56, marking an increase of 0.47.
• For Inventory Turnover Ratio (X), as of Mar 25, the value is 8.43. This value exceeds the healthy maximum of 8. It has increased from 3.08 (Mar 24) to 8.43, marking an increase of 5.35.
• For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 27.80. This value is within the healthy range. It has decreased from 82.98 (Mar 24) to 27.80, marking a decrease of 55.18.
• For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 25.06. This value is within the healthy range. It has decreased from 74.98 (Mar 24) to 25.06, marking a decrease of 49.92.
• For Earning Retention Ratio (%), as of Mar 25, the value is 72.20. This value exceeds the healthy maximum of 70. It has increased from 17.02 (Mar 24) to 72.20, marking an increase of 55.18.
• For Cash Earning Retention Ratio (%), as of Mar 25, the value is 74.94. This value exceeds the healthy maximum of 70. It has increased from 25.02 (Mar 24) to 74.94, marking an increase of 49.92.
• For Interest Coverage Ratio (X), as of Mar 25, the value is 44.28. This value is within the healthy range. It has increased from 29.70 (Mar 24) to 44.28, marking an increase of 14.58.
• For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 32.28. This value is within the healthy range. It has increased from 21.58 (Mar 24) to 32.28, marking an increase of 10.70.
• For Enterprise Value (Cr.), as of Mar 25, the value is 83,930.05. It has increased from 63,877.10 (Mar 24) to 83,930.05, marking an increase of 20,052.95.
• For EV / Net Operating Revenue (X), as of Mar 25, the value is 7.75. This value exceeds the healthy maximum of 3. It has increased from 6.62 (Mar 24) to 7.75, marking an increase of 1.13.
• For EV / EBITDA (X), as of Mar 25, the value is 35.76. This value exceeds the healthy maximum of 15. It has increased from 29.46 (Mar 24) to 35.76, marking an increase of 6.30.
• For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 7.76. This value exceeds the healthy maximum of 3. It has increased from 6.64 (Mar 24) to 7.76, marking an increase of 1.12.
• For Retention Ratios (%), as of Mar 25, the value is 72.19. This value exceeds the healthy maximum of 70. It has increased from 17.01 (Mar 24) to 72.19, marking an increase of 55.18.
• For Price / BV (X), as of Mar 25, the value is 21.15. This value exceeds the healthy maximum of 3. It has increased from 16.73 (Mar 24) to 21.15, marking an increase of 4.42.
• For Price / Net Operating Revenue (X), as of Mar 25, the value is 7.76. This value exceeds the healthy maximum of 3. It has increased from 6.64 (Mar 24) to 7.76, marking an increase of 1.12.
• For EarningsYield, as of Mar 25, the value is 0.01. This value is below the healthy minimum of 5. It has decreased from 0.02 (Mar 24) to 0.01, marking a decrease of 0.01.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Fair Value

*Investments are subject to market risks

Strength and Weakness